Alume Biosciences Inc

Alume Biosciences Inc has raised $27.1M in total funding. The most recent round was Series B.

Alume Biosciences Inc is headquartered in La Jolla, CA.

Nerve damage during surgery is common and severe — up to 60% of head-and-neck surgery patients and as many as 80% of prostate surgery patients experience temporary or permanent nerve-related complications like paralysis or incontinence.

Alume developed bevonescein (ALM-488), a compound given by IV before surgery that makes nerves glow so surgeons can see and preserve them, then clears from the body through the kidneys within hours.

Its nerve illumination technology originated from research by surgeon Dr. Quyen Nguyen and Nobel Laureate Dr. Roger Tsien, is now in Phase 3 clinical trials with an FDA submission planned for 2026, and is endorsed by named surgeons at Harvard, Duke, Vanderbilt, and Massachusetts General.

Founded and led by Dr. Quyen Nguyen, a UC San Diego head-and-neck surgeon named to Forbes' 50 Over 50 Innovation list.